| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
AQST
Aquestive Therapeutics
|
Jun 25, 2026 | BUY |
Strong Buy
+102.8% avg upside
10 analysts
|
$8.00
86.56% Upside
|
· |
|
SVRA
Savara
|
Jun 03, 2026 | BUY |
Strong Buy
+46.9% avg upside
17 analysts
|
$11.00
91.87% Upside
|
· |
|
DYN
Dyne Therapeutics
|
May 21, 2026 | BUY |
Strong Buy
+82.7% avg upside
30 analysts
|
$40.00
95.60% Upside
|
+17.0% |
|
KROS
Keros Therapeutics
|
May 11, 2026 | HOLD |
Buy
+136.1% avg upside
21 analysts
|
— | -12.6% |
|
MNPR
Monopar Therapeutics Inc
|
May 11, 2026 | HOLD |
Strong Buy
+12.4% avg upside
18 analysts
|
— | -9.5% |
|
GOSS
Gossamer Bio
|
May 11, 2026 | HOLD |
Hold
+4498.9% avg upside
17 analysts
|
— | +0.0% |
|
LQDA
Liquidia Technologies
|
May 11, 2026 | HOLD |
Strong Buy
-29.6% avg upside
15 analysts
|
— | +42.5% |
|
BNTC
Benitec Biopharma
|
May 11, 2026 | HOLD |
Buy
+112.5% avg upside
13 analysts
|
— | -4.9% |
|
LRMR
Larimar Therapeutics
|
May 11, 2026 | HOLD |
Strong Buy
+408.9% avg upside
21 analysts
|
— | -16.9% |
|
UTHR
United Therapeutics
|
May 11, 2026 | HOLD |
Strong Buy
-19.7% avg upside
26 analysts
|
— | -3.9% |
|
SPRY
ARS Pharmaceuticals
|
May 11, 2026 | HOLD |
Strong Buy
+154.1% avg upside
12 analysts
|
— | -13.6% |
|
MLTX
MoonLake Immunotherapeutics
|
May 11, 2026 | HOLD |
Strong Buy
+46.2% avg upside
20 analysts
|
— | +5.8% |
|
MNKD
MannKind
|
Apr 27, 2026 | HOLD |
Buy
+70.8% avg upside
22 analysts
|
— | +25.9% |
|
IFRX
InflaRx
|
Apr 24, 2026 | BUY |
Buy
+367.0% avg upside
11 analysts
|
$5.00
157.73% Upside
|
+60.8% |
|
TARS
Tarsus Pharmaceuticals
|
Apr 24, 2026 | BUY |
Strong Buy
+20.6% avg upside
16 analysts
|
$98.00
59.46% Upside
|
+3.8% |
|
IRD
Opus Genetics
|
Mar 16, 2026 | BUY |
Strong Buy
+160.5% avg upside
24 analysts
|
$10.00
150.69% Upside
|
-24.6% |
|
HRMY
Harmony Biosciences Holdings
|
Feb 25, 2026 | BUY |
Strong Buy
+31.6% avg upside
13 analysts
|
$62.00
76.29% Upside
|
+6.7% |
|
EVMN
Evommune, Inc.
|
Jan 23, 2026 | BUY |
Strong Buy
+99.8% avg upside
12 analysts
|
$42.00
72.86% Upside
|
+28.2% |
|
PRQR
ProQR
|
Nov 11, 2025 | BUY |
Strong Buy
+652.4% avg upside
18 analysts
|
$9.00
482.52% Upside
|
-32.6% |
|
SRPT
Sarepta Therapeutics
|
Oct 09, 2025 | BUY |
Buy
+264.2% avg upside
49 analysts
|
$37.00
129.45% Upside
|
-25.4% |
|
KALA
KALA BIO
|
Aug 11, 2025 | BUY |
Strong Buy
+8248.6% avg upside
9 analysts
|
$750.00
29721.17% Upside
|
-99.3% |
|
RANI
Rani Therapeutics Holdings
|
Jul 17, 2025 | HOLD |
Strong Buy
+1185.4% avg upside
10 analysts
|
— | +77.9% |
|
OPTEY
Opthea Limited Sponsored ADR
|
Mar 24, 2025 | HOLD |
Buy
+25042.8% avg upside
7 analysts
|
— | · |
|
KRRO
Korro Bio
|
Jan 10, 2025 | BUY |
Strong Buy
+118.2% avg upside
19 analysts
|
$155.00
1174.59% Upside
|
-73.1% |
|
CLSDQ
Clearside Biomedical
|
Nov 13, 2024 | BUY |
Hold
+14259.0% avg upside
10 analysts
|
$75.00
38361.58% Upside
|
-77.2% |
|
JBIO
Jade Biosciences
|
Aug 13, 2024 | HOLD |
Strong Buy
+157.2% avg upside
16 analysts
|
$105.00
386.93% Upside
|
-87.7% |
|
SGMO
Sangamo Therapeutics
|
Mar 14, 2024 | BUY |
Buy
+15048.7% avg upside
16 analysts
|
$2.00
2602.78% Upside
|
+25.6% |
|
OCS
Oculis Holding
|
Mar 06, 2024 | BUY |
Strong Buy
+220.5% avg upside
11 analysts
|
$29.00
142.65% Upside
|
+57.9% |
|
RGNX
RegenXBio
|
Mar 05, 2024 | HOLD |
Strong Buy
+263.1% avg upside
22 analysts
|
$21.00
109.78% Upside
|
-74.6% |
|
PCRX
Pacira Pharmaceuticals
|
Mar 01, 2024 | BUY |
Buy
+54.5% avg upside
21 analysts
|
$57.00
129.17% Upside
|
-16.7% |
|
BMRN
BioMarin Pharmaceutical
|
Feb 23, 2024 | HOLD |
Strong Buy
+60.3% avg upside
52 analysts
|
$80.00
36.65% Upside
|
-25.2% |
|
IMUX
Immunic
|
Feb 22, 2024 | BUY |
Strong Buy
+147.9% avg upside
21 analysts
|
$4.00
73.39% Downside
|
+4.1% |
|
ASND
Ascendis Pharma
|
Feb 08, 2024 | BUY |
Strong Buy
+3.6% avg upside
24 analysts
|
$225.00
12.98% Downside
|
-13.2% |
|
CALC
CalciMedica
|
Aug 25, 2022 | HOLD |
Buy
+3403.1% avg upside
9 analysts
|
— | -46.1% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.